BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Wang W, Li Q. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. J Exp Clin Cancer Res 2021;40:73. [PMID: 33596985 DOI: 10.1186/s13046-021-01873-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sukowati C, Cabral LKD, Tiribelli C. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Ann Hepatol 2022;27:100740. [PMID: 35809835 DOI: 10.1016/j.aohep.2022.100740] [Reference Citation Analysis]
2 Kang SM, Khalil L, El-Rayes BF, Akce M. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Front Oncol 2022;12:821903. [PMID: 35433430 DOI: 10.3389/fonc.2022.821903] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Xing R, Gao J, Cui Q, Wang Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol 2021;12:783236. [PMID: 34899747 DOI: 10.3389/fimmu.2021.783236] [Reference Citation Analysis]
5 Japir AAMM, Ke W, Li J, Mukerabigwi JF, Ibrahim A, Wang Y, Li X, Zhou Q, Mohammed F, Ge Z. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy. J Control Release 2021;339:418-29. [PMID: 34662586 DOI: 10.1016/j.jconrel.2021.10.015] [Reference Citation Analysis]
6 Zhang Y, Zhang T, Yin Q, Luo H. Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma. BMC Cancer 2021;21:1156. [PMID: 34711185 DOI: 10.1186/s12885-021-08893-3] [Reference Citation Analysis]
7 Lam M, Reales-Calderon JA, Ow JR, Adriani G, Pavesi A. In vitro 3D liver tumor microenvironment models for immune cell therapy optimization. APL Bioeng 2021;5:041502. [PMID: 34632251 DOI: 10.1063/5.0057773] [Reference Citation Analysis]
8 Davuluri GVN, Chen CC, Chiu YC, Tsai HW, Chiu HC, Chen YL, Tsai PJ, Kuo WT, Tsao N, Lin YS, Chang CP. Autophagy Drives Galectin-1 Secretion From Tumor-Associated Macrophages Facilitating Hepatocellular Carcinoma Progression. Front Cell Dev Biol 2021;9:741820. [PMID: 34552935 DOI: 10.3389/fcell.2021.741820] [Reference Citation Analysis]
9 Miao L, Zhang Z, Ren Z, Li Y. Application of Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:699060. [PMID: 34513678 DOI: 10.3389/fonc.2021.699060] [Reference Citation Analysis]